BD announces 5.4% increase in Q1 revenue

BD has published financial results for the first fiscal quarter, revealing that its revenues increased by 5.4 percent – or 3.7 percent on a currency-neutral basis – to $3.08 billion (GBP 2.22 billion).

The revenue result includes an estimated 110-basis-point adverse impact from recent changes in the company's US dispensing business model.

Looking at particular segments, the medical technology firm confirmed that revenues in the BD medical unit grew by 3.6 percent from a year earlier, to $2.035 billion.

Life sciences revenues rose by 9.1 percent year-on-year to $1.045 billion.

Revenues gained outside the US increased by 10.1 percent from a year earlier to $1.423 billion, while US growth was a more modest 1.6 percent, to $1.657 billion.

One of the most significant recent developments of the past year for BD was the acquisition of medical technology developer C.R. Bard.

Vincent Forlenza, chairman and CEO of BD, said: "We look forward to the future with confidence as we welcome C.R. Bard to BD. Together, through our combined capabilities and the impact we can have on our customers and their patients, we have a tremendous opportunity to advance the world of health."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.